Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8230891rdf:typepubmed:Citationlld:pubmed
pubmed-article:8230891lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:8230891lifeskim:mentionsumls-concept:C2709248lld:lifeskim
pubmed-article:8230891lifeskim:mentionsumls-concept:C0001455lld:lifeskim
pubmed-article:8230891lifeskim:mentionsumls-concept:C0031638lld:lifeskim
pubmed-article:8230891lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8230891lifeskim:mentionsumls-concept:C0055729lld:lifeskim
pubmed-article:8230891pubmed:issue8lld:pubmed
pubmed-article:8230891pubmed:dateCreated1993-12-3lld:pubmed
pubmed-article:8230891pubmed:abstractTextWe examined the effect of Cilostazol, a cyclic AMP phosphodiesterase inhibitor, rat isolated pulmonary arterial ring tone. Cilostazol dilated pulmonary arterial rings pre-contracted with 10(-6) M phenylephrine in a dose-dependent manner (ED50 3.00 x 10(-6) M). This vasodilatory effect of Cilostazol was not affected by pretreatment with meclofenamate (10(-5) M), mechanical endothelium denudation, methylene blue (10(-5) M) or nitro-L-arginine (2 x 10(-4) M). The vasodilatory effect of Cilostazol on rat thoracic aortic rings was stronger than that on rat pulmonary arterial ring (ED50 1.89 x 10(-6) M). Cilostazol (10(-6) M-10(-4) M) inhibited hypoxic contraction of rat pulmonary rings in a dose-dependent manner. Our experimental data indicated that Cilostazol caused vasodilation regardless of vascular endothelium function and inhibited hypoxic contraction due to inhibition of cyclic AMP phosphodiesterase.lld:pubmed
pubmed-article:8230891pubmed:languagejpnlld:pubmed
pubmed-article:8230891pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230891pubmed:citationSubsetIMlld:pubmed
pubmed-article:8230891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8230891pubmed:statusMEDLINElld:pubmed
pubmed-article:8230891pubmed:monthAuglld:pubmed
pubmed-article:8230891pubmed:issn0301-1542lld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:TakahashiHHlld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:OhnishiTTlld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:SakaiTTlld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:SasakiFFlld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:NakaiTTlld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:IshizakiTTlld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:MiyaboSSlld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:ShigemoriKKlld:pubmed
pubmed-article:8230891pubmed:authorpubmed-author:AmeshimaSSlld:pubmed
pubmed-article:8230891pubmed:issnTypePrintlld:pubmed
pubmed-article:8230891pubmed:volume31lld:pubmed
pubmed-article:8230891pubmed:ownerNLMlld:pubmed
pubmed-article:8230891pubmed:authorsCompleteYlld:pubmed
pubmed-article:8230891pubmed:pagination936-41lld:pubmed
pubmed-article:8230891pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:meshHeadingpubmed-meshheading:8230891-...lld:pubmed
pubmed-article:8230891pubmed:year1993lld:pubmed
pubmed-article:8230891pubmed:articleTitle[Effects of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on pulmonary vascular tone].lld:pubmed
pubmed-article:8230891pubmed:affiliationThird Department of Internal Medicine, Fukui Medical School, Japan.lld:pubmed
pubmed-article:8230891pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8230891pubmed:publicationTypeEnglish Abstractlld:pubmed